Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
328 DKK | +2.18% | +9.33% | +162.40% |
17/04 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
29/03 | Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024. | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+162.40% | 76Cr | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.34TCr | |
-1.40% | 2.21TCr | |
-8.21% | 1.83TCr | |
-41.70% | 1.66TCr | |
-15.33% | 1.6TCr | |
+5.80% | 1.4TCr | |
+28.03% | 1.17TCr |
- Stock Market
- Equities
- GUBRA Stock
- News Gubra A/S
- Gubra Seeks UK Regulatory Approval to Begin Human Trial for Anti-Obesity Drug